Market Research Logo

Post-Operative Pain - Pipeline Review, H1 2015

Post-Operative Pain - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Post-Operative Pain - Pipeline Review, H1 2015’, provides an overview of the Post-Operative Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Operative Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Operative Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Post-Operative Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Post-Operative Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Post-Operative Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Post-Operative Pain Overview
Therapeutics Development
Pipeline Products for Post-Operative Pain - Overview
Pipeline Products for Post-Operative Pain - Comparative Analysis
Post-Operative Pain - Therapeutics under Development by Companies
Post-Operative Pain - Therapeutics under Investigation by Universities/Institutes
Post-Operative Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Post-Operative Pain - Products under Development by Companies
Post-Operative Pain - Products under Investigation by Universities/Institutes
Post-Operative Pain - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
AngioChem Inc.
Boehringer Ingelheim GmbH
Cara Therapeutics, Inc.
Chong Kun Dang Pharmaceutical Corp.
Cytogel Pharma, LLC
DURECT Corporation
Echo Pharmaceuticals B.V.
Encore Therapeutics Inc.
Flexion Therapeutics, Inc.
Galleon Pharmaceuticals
Grunenthal GmbH
GW Pharmaceuticals plc
Heron Therapeutics, Inc.
Immupharma Plc
INSYS Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Medtronic, Inc.
Ocular Therapeutix, Inc.
Omeros Corporation
Orbis Biosciences, Inc.
Orion Oyj
Pharmazz, Inc.
PhytoHealth Corporation
Recro Pharma, Inc.
Rottapharm SpA
Takeda Pharmaceutical Company Limited
Thar Pharmaceuticals, Inc.
Trevena, Inc.
UMeWorld Limited
Post-Operative Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bupivacaine hydrochloride + meloxicam) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(dexketoprofen trometamol + tramadol hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ketoprofen + amitriptyline + oxymetazoline) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ketorolac tromethamine + phenylephrine hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AM-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-2002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-8028 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARX-8203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AYX-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-1026706 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bupivacaine hydrochloride SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
centhaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CKD-943 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CMX-020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-4056 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-845 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyt-1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone acetate SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexmedetomidine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E-52862 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fadolmidine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FX-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GAL-044 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GIBH-1014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
grapiprant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPP-102199 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketamine hydrochloride ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDT-10013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nabiximols - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nalbuphine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ropivacaine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ropivacaine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tapentadol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tramadol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRV-130 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VVZ-149 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post-Operative Pain - Recent Pipeline Updates
Post-Operative Pain - Dormant Projects
Post-Operative Pain - Discontinued Products
Post-Operative Pain - Product Development Milestones
Featured News & Press Releases
Nov 17, 2014: Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain
Oct 30, 2014: Omidria Granted Pass-Through Reimbursement Status from CMS
Oct 08, 2014: Ocular Therapeutix Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for Post-Operative Inflammation and Pain
Oct 08, 2014: Trevena Announces Early Completion of Enrollment of Phase 2a/b Study of TRV130 in Postoperative Pain
Sep 16, 2014: Trevena Granted Key U.S. Composition of Matter Patent for TRV130
Sep 04, 2014: Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN
Jul 16, 2014: Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain
May 14, 2014: Heron Therapeutics Reports Positive Results for Post-Surgical Pain Program
May 02, 2014: Trevena Presents Results from Phase 1b Trial of Injectable Analgesic TRV130 at American Society of Pain Annual Meeting
May 01, 2014: Trevena Initiates Phase 2 Study of TRV130 in Acute Postoperative Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post-Operative Pain, H1 2015
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Post-Operative Pain - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2015
Post-Operative Pain - Pipeline by Adynxx, Inc., H1 2015
Post-Operative Pain - Pipeline by AngioChem Inc., H1 2015
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H1 2015
Post-Operative Pain - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015
Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H1 2015
Post-Operative Pain - Pipeline by DURECT Corporation, H1 2015
Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H1 2015
Post-Operative Pain - Pipeline by Encore Therapeutics Inc., H1 2015
Post-Operative Pain - Pipeline by Flexion Therapeutics, Inc., H1 2015
Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H1 2015
Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2015
Post-Operative Pain - Pipeline by GW Pharmaceuticals plc, H1 2015
Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H1 2015
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2015
Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H1 2015
Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2015
Post-Operative Pain - Pipeline by Medtronic, Inc., H1 2015
Post-Operative Pain - Pipeline by Ocular Therapeutix, Inc., H1 2015
Post-Operative Pain - Pipeline by Omeros Corporation, H1 2015
Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H1 2015
Post-Operative Pain - Pipeline by Orion Oyj, H1 2015
Post-Operative Pain - Pipeline by Pharmazz, Inc., H1 2015
Post-Operative Pain - Pipeline by PhytoHealth Corporation, H1 2015
Post-Operative Pain - Pipeline by Recro Pharma, Inc., H1 2015
Post-Operative Pain - Pipeline by Rottapharm SpA, H1 2015
Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Post-Operative Pain - Pipeline by Thar Pharmaceuticals, Inc., H1 2015
Post-Operative Pain - Pipeline by Trevena, Inc., H1 2015
Post-Operative Pain - Pipeline by UMeWorld Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Post-Operative Pain Therapeutics - Recent Pipeline Updates, H1 2015
Post-Operative Pain - Dormant Projects, H1 2015
Post-Operative Pain - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Post-Operative Pain, H1 2015
Number of Products under Development for Post-Operative Pain - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report